Zinc and Its Antioxidant Properties: The Potential Use of Blood Zinc Levels as a Marker of Cancer Risk in BRCA1 Mutation Carriers-Reference-Cited by-同舟云学术

Zinc and Its Antioxidant Properties: The Potential Use of Blood Zinc Levels as a Marker of Cancer Risk in BRCA1 Mutation Carriers

Published:2024-05-16 Issue:5 Volume:13 Page:609
ISSN:2076-3921
Container-title:Antioxidants
language:en
Short-container-title:Antioxidants

Author:

Matuszczak Milena¹^ORCID,Kiljańczyk Adam¹,Marciniak Wojciech²^ORCID,Derkacz Róża²^ORCID,Stempa Klaudia¹,Baszuk Piotr¹,Bryśkiewicz Marta¹,Sun Ping³,Cheriyan Angela³,Cybulski Cezary¹²,Dębniak Tadeusz¹^ORCID,Gronwald Jacek¹²^ORCID,Huzarski Tomasz¹²⁴,Lener Marcin R.¹,Jakubowska Anna¹,Szwiec Marek⁵^ORCID,Stawicka-Niełacna Małgorzata⁴^ORCID,Godlewski Dariusz⁶,Prusaczyk Artur⁷,Jasiewicz Andrzej⁸^ORCID,Kluz Tomasz⁹^ORCID,Tomiczek-Szwiec Joanna¹⁰^ORCID,Kilar-Kobierzycka Ewa¹¹,Siołek Monika¹²,Wiśniowski Rafał¹³,Posmyk Renata¹⁴,Jarkiewicz-Tretyn Joanna¹⁵,Scott Rodney J.¹⁶^ORCID,Narod Steven A.³^ORCID,Lubiński Jan¹²^ORCID

Affiliation:

1. Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland

2. Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra, Poland

3. Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto, ON M5G 1N8, Canada

4. Department of Clinical Genetics and Pathology, University of Zielona Góra, ul. Zyty 28, 65-046 Zielona Góra, Poland

5. Department of Surgery and Oncology, University of Zielona Góra, Zyty 28, 65-046 Zielona Góra, Poland

6. OPEN, Kazimierza Wielkiego 24 St., 61-863 Poznań, Poland

7. Medical and Diagnostic Center, 08-110 Siedlce, Poland

8. Genetic Counseling Center, Subcarpatian Oncological Hospital, 18 Bielawskiego St., 36-200 Brzozów, Poland

9. Department of Gynecology, Gynecology Oncology and Obstetrics, Institute of Medical Sciences, Medical College, Rzeszow University, Rejtana 16c, 35-959 Rzeszow, Poland

10. Department of Histology, Department of Biology and Genetics, Faculty of Medicine, University of Opole, 45-040 Opole, Poland

11. Department of Oncology, District Specialist Hospital, Leśna 27-29 St., 58-100 Świdnica, Poland

12. Holycross Cancer Center, Artwińskiego 3 St., 25-734 Kielce, Poland

13. Regional Oncology Hospital, Wyzwolenia 18 St., 43-300 Bielsko Biała, Poland

14. Department of Clinical Genetics, Medical University of Bialystok, 15-089 Białystok, Poland

15. Non-Public Health Care Centre, Cancer Genetics Laboratory, 87-100 Toruń, Poland

16. Medical Genetics, Hunter Medical Research Institute, Priority Research Centre for Cancer Research, Innovation and Translation, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Pathology North, John Hunter Hospital, King and Auckland Streets, Newcastle, NSW 2300, Australia

Abstract

BRCA1 mutations predispose women to breast and ovarian cancer. The anticancer effect of zinc is typically linked to its antioxidant abilities and protecting cells against oxidative stress. Zinc regulates key processes in cancer development, including DNA repair, gene expression, and apoptosis. We took a blood sample from 989 female BRCA1 mutation carriers who were initially unaffected by cancer and followed them for a mean of 7.5 years thereafter. There were 172 incident cases of cancer, including 121 cases of breast cancer, 29 cases of ovarian cancers, and 22 cancers at other sites. A zinc level in the lowest tertile was associated with a modestly higher risk of ovarian cancer compared to women with zinc levels in the upper two tertiles (HR = 1.65; 95% CI 0.80 to 3.44; p = 0.18), but this was not significant. Among those women with zinc levels in the lowest tertile, the 10-year cumulative risk of ovarian cancer was 6.1%. Among those in the top two tertiles of zinc level, the ten-year cumulative risk of ovarian cancer was 4.7%. There was no significant association between zinc level and breast cancer risk. Our preliminary study does not support an association between serum zinc level and cancer risk in BRCA1 mutation carriers.

Funder

Minister of Science and Higher Education “Regional Initiative of Excellence”

Publisher

MDPI AG

Link

https://www.mdpi.com/2076-3921/13/5/609/pdf

Reference52 articles.

1. Cancer Statistics, 2023;Siegel;CA Cancer J. Clin.,2023

2. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers;Kuchenbaecker;JAMA,2017

3. Cancer Risks Associated with BRCA1 and BRCA2 Pathogenic Variants;Li;J. Clin. Oncol.,2022

4. Zinc: A Promising Agent in Dietary Chemoprevention of Cancer;Dhawan;Indian J. Med. Res.,2010

5. Pre-Diagnostic Copper and Zinc Biomarkers and Colorectal Cancer Risk in the European Prospective Investigation into Cancer and Nutrition Cohort;Stepien;Carcinogenesis,2017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review Article on Molecular Basis of Zinc and Copper Interactions in Cancer Physiology;Biological Trace Element Research;2024-08-31

2. Dietary Interventions for Cancer Prevention: An Update to ACS International Guidelines;Nutrients;2024-08-29

3. Antioxidant Properties of Zinc and Copper—Blood Zinc-to Copper-Ratio as a Marker of Cancer Risk BRCA1 Mutation Carriers;Antioxidants;2024-07-14